Stephen M. Novak, MS, MA 

Mr. Novak graduated from the University of Utah in Salt Lake City, Utah earning a BS in Psychology with a minor in Pre-medicine. He completed an MA in International Affairs from The Catholic University of America in Washington, DC, an MS in Information Management from Syracuse University in Syracuse, New York and a Chief Information Officer Certificate from the National Defense University in Washington, DC. 

Mr. Novak spent 22 years in the U.S. Army as a career Military Intelligence Officer and retired from the Pentagon as a Lieutenant Colonel. He served in key positions in Washington, D.C., across the United States and Europe and was responsible for numerous pivotal “Homeland” security initiatives. He worked directly for the Secretary of Defense and other influential leaders, such as Colin Powell, the Chairman of the Joint Chiefs of Staff while serving at the Pentagon in Washington, DC. 

He joined CBR International Corp.® in January 2011 as Vice President for Strategic Business Development. He was also the Founder and Managing Director of CBR Biotech Strategies GmbH. Founded in October 2013, CBR Biotech Strategies GmbH, in partnership with CBR International Corp®, was a European-based company that specialized in providing corporate strategy for overall product development for the biotech, pharmaceutical and device industries. During this period, Mr. Novak’s expertise and international network of experienced professionals focused on supporting US and international clients with European Medicines Agency (EMA) and US Food and Drug Administration (FDA) pharmaceutical regulatory representation. He facilitated the FDA required Bioresearch Monitoring Program (BIMO) Inspection for a US/EU clinical trial securing the FDA and EMA approvals for NeuraCeq™ for the early diagnosis of Alzheimer’s disease. In addition, he led the expert team of clinical, regulatory and scientific consultants providing ZMapp® (monoclonal antibody) for compassionate use during the West African Ebola outbreak, saving countless lives. Mr. Novak also supported the FDA approval for LaViv®, the 3rd autologous cell therapy in the US for the treatment of nasolabial folds.  During his tenure at CBR, he led successful FDA meetings for sponsors worldwide. 

Mr. Novak is an experienced Senior Leader with a solid track record of building and leading high-performance teams. He excels at creating positive work environments and achieving 100% employee retention rates. Mr. Novak has led several commercial and clinical groups, focusing on profit margin expansion of more than 20% year-over-year, while managing multiple biotech and pharmaceutical accounts with a value exceeding $100MM. He established a team of clinicians and subject matter experts, who provided digital planning, feasibility, and awareness to support Phase 1-4 clinical trials with global Real World Data (RWD). Mr. Novak created a growth strategy for mergers, acquisitions, and international agreements, building a global partnership with EPS Corporation, Japan’s largest contract research organization.  

Mr. Novak is an aviation enthusiast and is a current, Commercial Instrument-Rated Pilot.